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1. INTRODUCTION {#joa312164-sec-0005}
===============

The growing evidence of the importance of cardiac implantable electronic devices (CIEDs) in improving both quality of life and survival among specific patients with heart disease has led to a significant growth in the number of these implantations.[1](#joa312164-bib-0001){ref-type="ref"}, [2](#joa312164-bib-0002){ref-type="ref"} As a result, the number of complications, including CIED‐related infection, has also increased. Although transvenous lead extractions is safe and effective for patients with infections from implantable devices,[3](#joa312164-bib-0003){ref-type="ref"}, [4](#joa312164-bib-0004){ref-type="ref"} the mortality among these patients has been reported to be very high.[5](#joa312164-bib-0005){ref-type="ref"}, [6](#joa312164-bib-0006){ref-type="ref"}, [7](#joa312164-bib-0007){ref-type="ref"} In patients with lead‐related infective endocarditis, in particular, the mortality at 1‐5 years has been reported to range from 31% to 44%.[6](#joa312164-bib-0006){ref-type="ref"}, [8](#joa312164-bib-0008){ref-type="ref"}, [9](#joa312164-bib-0009){ref-type="ref"}, [10](#joa312164-bib-0010){ref-type="ref"}, [11](#joa312164-bib-0011){ref-type="ref"}, [12](#joa312164-bib-0012){ref-type="ref"}, [13](#joa312164-bib-0013){ref-type="ref"}, [14](#joa312164-bib-0014){ref-type="ref"} Therefore, it is important to know the prognosis of transvenous lead extractions as well as its influencing factors. Studies of lead extraction in Japanese patients have been reported.[15](#joa312164-bib-0015){ref-type="ref"}, [16](#joa312164-bib-0016){ref-type="ref"} However, the prognosis after transvenous lead extraction in Japanese patients, especially those with lead‐related infective endocarditis, has not been evaluated. Therefore, we sought to clarify the prognosis after transvenous lead extraction in Japanese patients on the basis of our experience at a single center.

2. METHODS {#joa312164-sec-0006}
==========

2.1. Patients {#joa312164-sec-0007}
-------------

The medical records of all patients with CIED infections who underwent transvenous lead extraction at the Okayama University Hospital from 2010 to 2017 were retrospectively reviewed. All patients were followed and managed by an electrophysiologist and an infectious disease physician. Blood cultures were obtained from all patients before initiating antibiotic therapy at the hospital. Cultures were also obtained from the fibrotic capsule of the device pocket and from the lead tip as well as the attached fibrotic tissue at the time of the device removal. All patients underwent transesophageal echocardiography to confirm the existence or size of vegetation. Survival data were obtained using electronic medical records. The study proposal was approved by the Okayama University Hospital Institutional Review Board.

2.2. Definitions {#joa312164-sec-0008}
----------------

The patients were divided to two groups: those with lead‐related infective endocarditis and those with infection only of the device pocket. A pocket infection was defined as the presence of local warmth, erythema, swelling, edema, and pain in or discharge from the device pocket or an erosion or impending erosion of the device without lead‐related infective endocarditis. Lead‐related infective endocarditis was diagnosed using the modified Duke criteria for diagnosis of infective endocarditis on the device leads in compliance with the ESC 2015 guidelines.[17](#joa312164-bib-0017){ref-type="ref"}, [18](#joa312164-bib-0018){ref-type="ref"} The diagnosis of lead‐related infective endocarditis was definite in the presence of two major criteria or one major criterion and three minor criteria. Patients who met one major and one minor criterion, or three minor criteria were also evaluated. Then, pocket infection group consisted of patients with pocket infection and without lead‐related infective endocarditis, and lead‐related infective endocarditis group consisted of patients with lead‐relate infective endocarditis and with or without pocket infection.

2.3. Lead extraction procedure {#joa312164-sec-0009}
------------------------------

Laser sheaths were employed in all cases when the leads could not be explanted by traction alone. In brief, the lead was prepared by inserting a locking stylet into the inner coil lumen when possible. A suture was tied onto the insulation and locking stylet at two sites. The laser sheath was advanced over the lead. Laser application was performed at the binding sites and advanced gradually from one binding site to another until the tip of the lead was reached. Once abutting the myocardium, a combination of traction and counter‐traction was performed, and the lead was freed. If laser sheaths were not advanced, mechanical sheaths were used. The femoral and jugular approaches were also attempted with snares.[19](#joa312164-bib-0019){ref-type="ref"} In cases with large vegetation (\>2 cm), hybrid therapy was used. Initially, lead dissection up to the upper superior vena cava was performed using the laser or mechanical sheaths. Next, open‐heart surgery was performed by a cardiovascular surgeon. The procedural and clinical success definitions in this study were based on the 2009 and 2017 HRS expert consensus statements.[20](#joa312164-bib-0020){ref-type="ref"}, [21](#joa312164-bib-0021){ref-type="ref"} Complete procedure success was defined as "lead extraction procedure with removal of all targeted leads and all lead material from the vascular space, with the absence of any permanently disabling complication or procedure‐related death." Clinical success was defined as "lead extraction procedures with removal of all targeted leads and lead material from the vascular space or retention of a small portion of the lead (\<4 cm) that does not negatively impact the outcome goals of the procedure." Failure was defined as "lead extraction procedures in which complete procedural or clinical success cannot be achieved, or the development of any permanently disabling complication or procedure‐related death."

2.4. After total lead extraction {#joa312164-sec-0010}
--------------------------------

In general, patients with pocket infection were treated with intravenous antibiotics for a minimum of 2 weeks after extraction, and patients with lead‐related infective endocarditis were treated for 4‐6 weeks. Intravenous antibiotic infusion was continued in patients with lead‐related infective endocarditis until the infection was eradicated. After eradication, if necessary, a new device was implanted.

2.5. Statistical analysis {#joa312164-sec-0011}
-------------------------

Continuous variables are expressed as mean ± standard deviation if they presented a normal distribution in the Kurtosis and Kolmogorov‐Smirnov tests and as median and interquartile ranges if they did not. Accordingly, the significance of between‐group differences was assessed with a two‐tailed Student\'s *t* test, or the equivalent nonparametric test, as appropriate. Discrete variables are expressed as frequencies and percentages, and the significance of a different distribution was determined by the chi‐squared or Fisher\'s exact test (as appropriate) for binary variables and the Mann‐Whitney test for ordinal variables. Survival and cumulative hazards were calculated using the Kaplan--Meier Method. Log‐rank tests were adopted to assess between‐group survival, and Cox proportional hazards regression analysis was performed to determine characteristics that were related to the outcome. Hazards ratios are reported with 95% confidence intervals (95% CI). All statistical analyses were performed using SPSS version 24.0 software (SPSS, Chicago, IL). Values of *P* \< 0.05 were considered statistically significant.

3. RESULTS {#joa312164-sec-0012}
==========

3.1. Patient characteristics {#joa312164-sec-0013}
----------------------------

Of the 107 patients included in this study, 32 were in the lead‐related infective endocarditis group and 75 were in the pocket infection group. There were significantly more patients with implantable cardioverter defibrillators in the lead‐related infective endocarditis group. Fever C‐reactive protein, and procalcitonin levels were higher; and hemoglobin, albumin levels were lower in the lead‐related infective endocarditis. There were no significant differences in other parameters between the two groups (Table [1](#joa312164-tbl-0001){ref-type="table"}).

###### 

Patient characteristics

                                     Total                Lead‐related infective endocarditis   Pocket infection     *P*
  ---------------------------------- -------------------- ------------------------------------- -------------------- ----------
  N                                  107                  32                                    75                   
  Male, n (%)                        84 (78.5)            26 (81.3)                             58 (77.3)            0.799
  Age, y                             72.8 ± 13.3          69.7 ± 14.3                           74.1 ± 12.8          0.116
  Height, m                          1.61 ± 0.10          1.63 ± 0.10                           1.61 ± 0.11          0.312
  Weight, kg                         58.4 ± 13.8          60.8 ± 15.8                           57.3 ± 12.8          0.228
  Body mass index, kg/m^2^           22.2 ± 3.8           22.7 ± 4.3                            22.0 ± 3.6           0.399
  NYHA class, n (%)                                                                                                  0.322
  I                                  88 (82.2)            26 (81.3)                             62 (82.7)            
  II                                 8 (7.5)              4 (12.5)                              4 (5.3)              
  III                                11 (10.3)            2 (6.3)                               9 (12.0)             
  IV                                 0 (0)                0 (0)                                 0 (0)                
  Ejection fraction (%)              56.8 ± 14.9          54.8 ± 16.5                           56.8 ± 14.9          0.407
  Log BNP                            2.0 ± 0.6            2.0 ± 0.7                             2.0 ± 0.5            0.610
  Serum BUN, mg/dL                   21.4 ± 11.8          20.9 ± 11.0                           21.7 ± 12.1          0.766
  Serum creatinine, mg/dL            1.10 ± 0.73          1.14 ± 0.60                           1.09 ± 0.78          0.740
  eGFR, mL/min                       58.2 ± 21.0          56.8 ± 21.5                           58.9 ± 20.9          0.643
  White blood cell, 10^3^            6.77 ± 3.68          8.13 ± 5.19                           6.19 ± 2.65          0.051
  Hemoglobin, g/dL                   12.2 ± 2.1           11.6 ± 2.1                            12.5 ± 2.0           0.049
  Platelet, 10^4^                    18.5 ± 8.0           17.0 ± 8.6                            19.1 ± 7.6           0.213
  Total protein, g/dL                6.6 ± 1.6            6.3 ± 1.4                             6.7 ± 1.7            0.323
  Albumin, g/dL                      3.6 ± 0.7            3.2 ± 0.9                             3.8 ± 0.5            \<0.001
  C‐reactive protein, mg/dL          2.8 ± 5.6            5.7 ± 7.4                             1.6 ± 4.0            0.005
                                     0.4 \[0.1‐1.8\]      0.4 \[0.1‐1.8\]                       1.3 \[0.3‐7.7\]      \<0.001
  HbA1c (%)                          6.0 ± 1.3            6.1 ± 0.99                            6.0 ± 1.4            0.704
  Vegetation, n (%)                  25 (23.4)            25 (78.1)                             ---                  ---
  Size, mm                                                13 \[7.8‐28.5\]                                            
  Period of antibiotics therapy, d   28 \[21‐36.25\]      29 \[22‐40\]                          28 \[20‐35\]         0.042
  Number of antibiotics types        2 \[1‐3\]            2 \[3 ‐5\]                            1 \[1‐2\]            \< 0.001
  Cefazolin                          82 (76.6)            21 (65.6)                             61 (81.3)            0.079
  Vancomycin                         24 (22.4)            12 (37.5)                             12 (16.0)            0.015
  Comorbidity, n (%)                                                                                                 
  Hypertension                       56 (52.3)            16 (50.0)                             40 (53.3)            0.834
  Diabetes mellitus                  30 (28.0)            8 (25.0)                              22 (29.3)            0.815
  Dyslipidemia                       25 (23.4)            9 (28.1)                              16 (21.3)            0.463
  Hemodialysis                       1 (0.9)              0 (0.0)                               1 (1.3)              1.000
  Obstructive pulmonary disease      19 (17.8)            2 (6.3)                               17 (22.7)            0.053
  Oral corticosteroid                5 (4.7)              1 (3.1)                               4 (5.3)              1.000
  Type of CIED, n (%)                                                                                                0.004
  PM                                 81 (75.7)            19 (59.4)                             62 (82.7)            
  ICD                                14 (13.1)            10 (31.3)                             4 (5.3)              
  CRT‐D                              9 (8.4)              2 (6.3)                               7 (9.3)              
  CRT‐P                              3 (2.8)              1 (3.1)                               2 (2.7)              
  Number of implanted lead, n (%)    2.1 ± 0.8            2.2 ± 0.8                             2.1 ± 0.9            0.612
  Lead dwelling time, y              8.4 ± 7.0, n = 227   8.6 ± 7.1, n = 70                     7.8 ± 6.8, n = 157   0.439

Values are mean ± standard deviation, median \[interquartile range\] or number (%) of patients.

BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CIED, cardiac implantable electronic device; CRT‐D, cardiac resynchronization therapy with defibrillator; CRT‐P, cardiac resynchronization therapy without defibrillator; GFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; PM, pacemaker. \[Correction added on 01 Aug 2019, after first online publication: the data for "Lead dwelling time, y" has been amended accordingly.\]
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3.2. Lead extraction {#joa312164-sec-0014}
--------------------

A total of 227 leads were extracted by various lead extraction techniques (Figure [1](#joa312164-fig-0001){ref-type="fig"}). Of these, 146 (46.7%) were active fixation leads and 121 (53.3%) were passive fixation leads, and 186 (84.1%) were pacemaker leads, 29 (12.7%) were ICD leads, and 12 (3.2%) were coronary sinus leads. The mean and median dwelling time were 8.4 ± 7.0 and 6.4 (interquartile; 3.1‐11.5) years, respectively. Mean dwelling time of leads was not different between lead‐related infective endocarditis group and pocket infection group (7.8 ± 6.8 years, n = 70 vs 8.6 ± 7.1 years, n = 157, *P* = 0.439). Overall, 222 (97.8%) of the leads were completely extracted. A small segment (\<4 cm) of the lead material was retained in four (1.7%) cases, which did not negatively impact the outcomes of the procedure. A large segment (≥4 cm) of the lead material was retained in one case, which did not negatively impact the outcomes of the procedure.

![The lead extraction technique. Various procedures were employed, not only locking stylet, laser sheath, but mechanical sheath, snare, femoral approach, jugular approach, and surgical approach](JOA3-35-654-g001){#joa312164-fig-0001}

Table [2](#joa312164-tbl-0002){ref-type="table"} presents the results of lead extraction per patient. A total of 109 extraction procedures were performed in 107 patients; two patients had a second procedure because of failure of the first. There were no significant differences between the groups in terms of complete procedure success rate, clinical success rate, or major and minor complications. Neither procedure‐related deaths nor permanently disabling complications were reported.

###### 

Results of lead extraction procedure

                                                           Total        Lead‐related infective endocarditis   Pocket infection   *P*
  -------------------------------------------------------- ------------ ------------------------------------- ------------------ -------
  N                                                        109          32                                    75                 
  Complete procedural success, n (%)                       102 (93.6)   32 (100)                              70 (90.9)          0.211
  Clinical success, n (%)                                  106 (97.2)   32 (100)                              74 (96.1)          0.554
  Major complications, n (%)                               3 (2.8)      2 (6.3)                               1 (1.3)            0.206
  Cardiac tamponade                                        3 (2.8)      2 (6.3)                               1 (1.3)            0.206
  Procedure related death                                  0 (0)        0 (0)                                 0 (0)              1.000
  Minor complications, n (%)                               9 (8.3)      1 (3.1)                               8 (10.4)           0.278
  Pericardial effusion not requiring intervention          2 (1.8)      0 (0.0)                               2 (2.6)            1.000
  Pocket hematoma at the surgical site                     2 (1.8)      0 (0.0)                               2 (2.6)            1.000
  Vascular repair at venous entry site                     1 (0.9)      0 (0.0)                               1 (1.3)            1.000
  Blood transfusion                                        3 (2.8)      0 (0.0)                               3 (3.9)            0.554
  Pulmonary embolism not requiring surgical intervention   1 (0.9)      1 (3.1)                               0 (0.0)            0.294
  Femoral vein dissection                                  1 (0.9)      0 (0.0)                               1 (1.3)            1.000

Two patients undertook second lead extraction procedure due to first procedure failure.
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3.3. Prognosis after lead extraction {#joa312164-sec-0015}
------------------------------------

Prognosis after lead extraction on the basis of infection type is shown in Table [3](#joa312164-tbl-0003){ref-type="table"} and Figure [2](#joa312164-fig-0002){ref-type="fig"}. Time to reimplantation, duration of hospital stay, and duration of antibiotics therapy were significantly longer in the lead‐related infective endocarditis group than in the pocket infection group. Number of administered antibiotics and patients with catecholamine usage for septic shock were more in the lead‐related infective endocarditis group than in the pocket infection group (Table [3](#joa312164-tbl-0003){ref-type="table"}).

###### 

Prognosis after lead extraction

                                                  Total              Lead‐related infective endocarditis   Pocket infection   *P*
  ----------------------------------------------- ------------------ ------------------------------------- ------------------ ---------
  N                                               107                32                                    75                 
  Reimplantation, n (%)                           81 (75.7)          22 (68.8)                             63 (84.0)          0.115
  Time to reimplantation, d                       18 \[14‐28.5\]     34 \[18.75‐126.25\]                   15 \[14‐22\]       \<0.001
  Duration of hospital stay, d                    38 \[31‐50\]       46 \[31.25‐84\]                       36 \[31‐45\]       0.006
  Duration of antibiotics therapy, d              28 \[21‐36.25\]    29 \[22‐40\]                          28 \[20‐35\]       0.042
  Number of antibiotics types                     2 \[1‐3\]          2 \[3 ‐5\]                            1 \[1‐2\]          \<0.001
  Catecholamine for septic shock, n (%)           6 (5.7)            6 (18.8)                              0 (0)              \<0.001
  Follow‐up periods after lead extraction, days   816 \[211‐1311\]   622 \[192.25‐1038\]                   882 \[215‐1372\]   0.118
  All cause death, n (%)                          21 (19.6)          7 (21.9)                              14 (18.7)          0.791
  Hospital death                                  0 (0)              0 (0)                                 0 (0)              1.000
  Death within 30 d                               0 (0)              0 (0)                                 0 (0)              1.000
  Death within 1 y                                6 (5.6)            2 (6.3)                               4 (5.3)            1.000
  Cause of death, n (%)                                                                                                       
  CIED infection related death                    0 (0)              0 (0)                                 0 (0)              1.000
  Cardiac death                                   4 (3.7)            2 (6.3)                               2 (2.7)            0.581
  Non‐cardiac death                               14 (13.1)          5 (15.6)                              9 (12.0)           0.755
  Unknown                                         3 (2.9)            0 (0)                                 3 (4.0)            0.553

Values are mean ± standard deviation, median (interquartile range) or number (%) of patients.

CIED, cardiac implantable electronic device.
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![Survival after lead extraction. A, Survival at 1 y after lead extraction between the lead‐related infective endocarditis (LRIE) and pocket infection[23](#joa312164-bib-0023){ref-type="ref"} groups. B, Survival at median of 816 d after lead extraction between the LRIE and PI groups. Survival rate was not significantly different at 1 y or at median of 816 d of follow‐up between the two groups (LRIE vs PI; 93.7% vs 94.7%, *P* = 1.000, at 1 y; 78.1% vs 81.3%, *P* = 0.791, at median of 816 d)](JOA3-35-654-g002){#joa312164-fig-0002}

The survival rate was not significantly different at 1 year or at the median 816 days of follow‐up between the lead‐related infective endocarditis and pocket infection groups: 93.7% vs 94.7%, *P* = 1.000, at 1 year, and 78.1% vs 81.3%, *P* = 0.791, at the median of 816 days, respectively (Figure [2](#joa312164-fig-0002){ref-type="fig"}). There was no death for 30 days after lead extraction. There was no death associated with implantable device infection during the median of 816 days of follow‐up. In lead‐related infective endocarditis group, only two patients died within 1 year: one due to intestinal bleeding 363 days after lead extraction, which was not related to CIED infection and the other due to aspiration pneumonia 86 days after lead extraction, which was not related to CIED infection. The main cause of other deaths was noncardiac death (Table [3](#joa312164-tbl-0003){ref-type="table"}).

On the univariate Cox regression analysis for mortality after lead extraction, age, log of brain natriuretic peptides, serum blood urea nitrogen, estimated glomerular filtration rate, hemoglobin, albumin, platelet, and hypertension were identified as predictors of mortality. (Table [4](#joa312164-tbl-0004){ref-type="table"}) Multivariate analysis could not be conducted due to small number of events.

###### 

Univariate Cox regression analysis for mortality after lead extraction

                                           Univariate                     
  ---------------------------------------- ------------ ----------------- ----------
  Male, n                                  1.033        \[0.378‐2.825\]   0.949
  Age, y                                   1.080        \[1.016‐1.147\]   0.013
  Height, m                                0.968        \[0.927‐1.011\]   0.141
  Weight, kg                               0.993        \[0.963‐1.024\]   0.655
  Body mass index, kg/m^2^                 1.031        \[0.925‐1.150\]   0.579
  NYHA class, III/IV, n                    1.845        \[0.675‐5.043\]   0.232
  Ejection fraction (%)                    0.977        \[0.952‐1.002\]   0.072
  Log BNP                                  4.180        \[1.907‐9.176\]   \< 0.001
  Serum BUN, mg/dL                         1.086        \[1.049‐1.125\]   \< 0.001
  Serum creatinine, mg/dL                  1.182        \[1.182‐1.680\]   0.351
  eGFR, mL/min                             0.974        \[0.954‐0.955\]   0.015
  White blood cell, 10^3^                  1.099        \[0.986‐1.226\]   0.088
  Hemoglobin, g/dL                         0.773        \[0.621‐0.963\]   0.002
  Platelet, 10^4^                          0.993        \[0.986‐1.000\]   0.045
  Total protein, g/dL                      0.924        \[0.758‐1.126\]   0.460
  Albumin, g/dL                            0.361        \[0.212‐0.616\]   \< 0.001
  HbA1c (%)                                1.034        \[0.770‐1.388\]   0.823
  C‐reactive protein, mg/dL                1.047        \[0.986‐1.112\]   0.133
  Procalcitonin, ng/mL                     1.129        \[0.868‐1.467\]   0.412
  Fever at administration                  1.430        \[0.862‐2.373\]   0.189
  Period of antibiotics therapy, d         1.006        \[0.999‐1.014\]   0.181
  Number of antibiotics types              1.164        \[0.991‐1.367\]   0.101
  Catecholamine for septic shock, n (%)    2.112        \[0.483‐9.234\]   0.366
  Vegetation, n                            0.709        \[0.208‐2.415\]   0.583
  Comorbidity, n                                                          
  Hypertension                             2.741        \[1.063‐7.071\]   0.037
  Diabetes mellitus                        2.221        \[0.942‐5.240\]   0.068
  Dyslipidemia                             0.950        \[0.342‐2.557\]   0.895
  Obstructive pulmonary disease            0.993        \[0.334‐2.956\]   0.990
  Oral corticosteroid                      1.255        \[0.165‐9.518\]   0.826
  CRT, n                                   2.240        \[0.818‐6.130\]   0.116
  Number of implanted lead, n              1.033        \[0.593‐1.798\]   0.909
  Lead‐related infective endocarditis, n   1.607        \[0.641‐4.026\]   0.311
  Reimplantation, n                        0.705        \[0.232‐2.142\]   0.538

Values are mean ± standard deviation, median (interquartile range) or number (%) of patients.

BNP, brain natriuretic peptide; BUN, denotes blood urea nitrogen; CI, confidence interval; CRT, cardiac resynchronization therapy with or without defibrillator; GFR, glomerular filtration rate; HR, denotes hazard ratio; NYHA, New York Heart Association.
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3.4. A case of lead‐related infective endocarditis {#joa312164-sec-0016}
--------------------------------------------------

A case of severe lead‐related infective endocarditis is shown in Figure [3](#joa312164-fig-0003){ref-type="fig"}. Various infections developed despite intravenous antibiotics therapy. After antibiotics had been continued for 8 months, the infection was no longer evident and a new device was implanted. Infection has not reoccurred.

![A case of severe lead‐related infective endocarditis. A 68 year old patient with cardiac resynchronization therapy with defibrillator was referred to Okayama University Hospital due to infective endocarditis. He suffered from pulmonary embolism, pulmonary abscess, septic shock, and disseminated intravascular coagulation. On the next day of admission, all leads were extracted without any complication. Methicillin‐sensitive *Staphylococcus aureus* was found on blood, sputum, urine, lead, and generator cultures. Although intravenous antibiotics have been continued, various infections developed. A, Vegetation in the superior vena cava and coronary sinus after lead extraction. B, Pulmonary abscess. C, Drainage of pulmonary abscess. D, Drainage of abscess beneath the scapula. E, Drainage of abscess around the vertebral body. F, Drainage of abscess around the pelvis. Vertebritis and discitis (not shown in Figure [3](#joa312164-fig-0003){ref-type="fig"}) also developed after the above infections disappeared. With continued antibiotics for 8 mo, the infection was no longer evident, and a new device was implanted. Infection has not reoccurred](JOA3-35-654-g003){#joa312164-fig-0003}

4. DISCUSSION {#joa312164-sec-0017}
=============

The main finding of this study was that the prognosis in Japanese patients with lead‐related infective endocarditis is as favorable as that in patients with only pocket infection.

4.1. Lead extraction techniques {#joa312164-sec-0018}
-------------------------------

In our institute, various lead extraction techniques are available, including the locking stylet, laser sheath, mechanical sheath, snare, femoral approach, jugular approach, and surgical approach. There were no procedure‐related deaths, in‐hospital deaths, or deaths within 30 days, which is better than the findings previously reported.[3](#joa312164-bib-0003){ref-type="ref"}, [4](#joa312164-bib-0004){ref-type="ref"} Our staff have been well‐trained by special experts in the field, and we could therefore apply various lead extraction techniques. This strategy no doubt greatly contributed to the good result obtained for the lead extraction procedures. In addition, we were able to communicate with the cardiovascular surgeons and anesthesiologists before or during the extractions, which could also have contributed to the good result. The timing of the extraction depended on the severity of the infection. For more severe infections, the extraction was performed earlier, as early lead extraction in patients with lead‐related infective endocarditis was recommended in a previous study.[14](#joa312164-bib-0014){ref-type="ref"}

4.2. Prognosis after lead extraction {#joa312164-sec-0019}
------------------------------------

The prognosis for patients with lead‐related infective endocarditis has been reported to be poor despite lead successful extraction. Survival probability at 1 year has been reported to range from 71% to 85% in these patients.[7](#joa312164-bib-0007){ref-type="ref"}, [8](#joa312164-bib-0008){ref-type="ref"}, [9](#joa312164-bib-0009){ref-type="ref"}, [10](#joa312164-bib-0010){ref-type="ref"}, [11](#joa312164-bib-0011){ref-type="ref"}, [12](#joa312164-bib-0012){ref-type="ref"}, [13](#joa312164-bib-0013){ref-type="ref"}, [14](#joa312164-bib-0014){ref-type="ref"}, [18](#joa312164-bib-0018){ref-type="ref"} However, in this study, survival probability at 1 year was 96.9%. Moreover, the factors associated with severity of heart failure, such as ejection fraction (EF),[22](#joa312164-bib-0022){ref-type="ref"} type of device, or New York Heart Association (NYHA) class were not predictors for mortality in the univariate Cox regression analysis. The factors associated with severity of infection, such as C‐reactive protein, vegetation, and lead‐related infective endocarditis, were also not identified as predictors (Table [4](#joa312164-tbl-0004){ref-type="table"}). Previously, increased age, low EF, heart failure, chronic renal failure, diabetes mellitus, obstructive pulmonary disease, and high NYHA class were reported to be associated with a poor prognosis in patients with infection from CIEDs.[7](#joa312164-bib-0007){ref-type="ref"}, [8](#joa312164-bib-0008){ref-type="ref"}, [9](#joa312164-bib-0009){ref-type="ref"}, [10](#joa312164-bib-0010){ref-type="ref"}, [11](#joa312164-bib-0011){ref-type="ref"}, [12](#joa312164-bib-0012){ref-type="ref"}, [13](#joa312164-bib-0013){ref-type="ref"}, [14](#joa312164-bib-0014){ref-type="ref"}, [18](#joa312164-bib-0018){ref-type="ref"} In this study, we identified age, chronic renal failure, anemia, and hypertension as predictors for mortality in the univariate Cox regression analysis. The death events were too few in this study to perform the multivariate analysis. Then, it is impossible to demonstrate each variable was truly associated with mortality because confounding factors were not adjusted.

4.3. Reasons of favorable prognosis in patients with lead‐related infective endocarditis after lead extraction {#joa312164-sec-0020}
--------------------------------------------------------------------------------------------------------------

Although there was no clear reason why the prognosis was favorable in this study compared to that previously reported (Table [5](#joa312164-tbl-0005){ref-type="table"}), there are some possible explanations. First, the patients could be hospitalized until the infection was completely eradicated, as shown in Figure [3](#joa312164-fig-0003){ref-type="fig"}. This is a beneficial aspect of the Japanese National Health Insurance. The maximum duration of hospitalization was 282 days. However, it is difficult to compare this finding to those in previous studies because of a lack of information regarding the duration of hospitalization.[7](#joa312164-bib-0007){ref-type="ref"}, [8](#joa312164-bib-0008){ref-type="ref"}, [9](#joa312164-bib-0009){ref-type="ref"}, [10](#joa312164-bib-0010){ref-type="ref"}, [11](#joa312164-bib-0011){ref-type="ref"}, [12](#joa312164-bib-0012){ref-type="ref"}, [13](#joa312164-bib-0013){ref-type="ref"}, [14](#joa312164-bib-0014){ref-type="ref"}, [18](#joa312164-bib-0018){ref-type="ref"} Second, during hospitalization, extraction team including various specialists, such as cardiovascular surgeons, anesthesiologists, plastic surgeons, respiratory surgeons, and especially infectious disease physicians, could contribute to the management of the infection. Third, most patients in this study were referred to our hospital from other hospitals. Patients with infection who received their implants in our hospital were only 7 (6.5%) out of 107 patients. Therefore, patients who were too sick to be transferred to our hospital may have been excluded. However, some patients with severe sepsis and disseminated intravascular coagulation (Table [3](#joa312164-tbl-0003){ref-type="table"}, Figure [3](#joa312164-fig-0003){ref-type="fig"}) were included in this study. Finally, although patient characteristics in this study that would influence the prognosis, such as age, EF, renal injury, diabetes mellitus, and obstructive pulmonary disease, were similar to those in previous studies, the rate of heart failure seemed to be lower[7](#joa312164-bib-0007){ref-type="ref"}, [8](#joa312164-bib-0008){ref-type="ref"}, [9](#joa312164-bib-0009){ref-type="ref"}, [10](#joa312164-bib-0010){ref-type="ref"}, [11](#joa312164-bib-0011){ref-type="ref"}, [12](#joa312164-bib-0012){ref-type="ref"}, [13](#joa312164-bib-0013){ref-type="ref"}, [14](#joa312164-bib-0014){ref-type="ref"}, [18](#joa312164-bib-0018){ref-type="ref"} although statistical analysis was not conducted.

###### 

Studies reporting long‐term prognosis after lead extraction for CIED infection

  Study                                                              Design          Patients, n   Systemic infection (%)   Local infection (%)   Criteria for systemic infection                                       30‐day mortality (%)   1‐year mortality (%)   3‐year mortality (%)
  ------------------------------------------------------------------ --------------- ------------- ------------------------ --------------------- --------------------------------------------------------------------- ---------------------- ---------------------- ----------------------
  Le et al., 2011[14](#joa312164-bib-0014){ref-type="ref"}           Retrospective   416           N.R.                     N.R.                  N.R.                                                                  4.5                    13.2                   N.A.
  Deharo et al., 2012[6](#joa312164-bib-0006){ref-type="ref"}        Prospective     197           58.9                     41.1                  Possible/definite IE (Duke criteria)                                  6.9                    14.3                   N.A.
  Maytin et al., 2012[12](#joa312164-bib-0012){ref-type="ref"}       Retrospective   985           18.0                     32.0                  Bacteremia and/or IE                                                  5.1                    20.2                   49.0
  Deckx et al., 2014[7](#joa312164-bib-0007){ref-type="ref"}         Retrospective   176           17.6                     34.7                  N.R.                                                                  6.5                    15.2                   N.A.
  Tarakji et al., 2014[8](#joa312164-bib-0008){ref-type="ref"}       Retrospective   502           42.0                     58.0                  Systemic signs/symptoms + History + Microbiology + echocardiography   5.8                    20.0                   N.A.
  Narducci et al., 2017[13](#joa312164-bib-0013){ref-type="ref"}     Prospective     217           64.0                     31.0                  Bacteremia and/or IE (modified Duke criteria)                         5.0                    10.0                   N.A.
  Polewczyk et al., 2017[10](#joa312164-bib-0010){ref-type="ref"}    Retrospective   500           80                       0                     Possible/definite IE (Duke criteria)                                  3.8                    N.R.                   29.3
  Diemberger et al., 2018[11](#joa312164-bib-0011){ref-type="ref"}   Prospective     121           45.5                     54.5                  Possible/definite IE (Duke criteria)                                  0.83                   14.2                   28.4
  Nishii et al. (present study)                                      Retrospective   107           30.0                     70.0                  Possible/definite IE (Duke criteria)                                  0.0                    5.6                    15.0

CIED, cardiac implantable electronic device; IE infective endocarditis; N.A., not available; N.R., not reported.

John Wiley & Sons, Ltd

4.4. Limitations {#joa312164-sec-0021}
----------------

This study has some limitations. First, this was a single‐center, retrospective study that included a small number of patients in a Japanese population, so the study may not have sufficient power to detect all predictors for mortality. Although in univariate analysis, some risk factors were shown, it is impossible to demonstrate each variable was truly associated with mortality because confounding factors were not adjusted. A prospective, multicenter study with a larger number of Japanese patients could increase the reliability of these results. Second, the number of deaths may be too small to gain enough statistical power. Then, other predictors for mortality may come out, if the number of death increased. Lastly, the background of patients was not same as the previous studies, then, it is difficult to precisely compare the mortality to the previous studies. However, the study was real‐world data in Japanese patients.

4.5. Conclusions {#joa312164-sec-0022}
----------------

The prognosis after lead extraction for patients with lead‐related infective endocarditis is favorable. Thus, lead extraction should be strongly recommended, even in patients with lead‐related infective endocarditis in a generally poor condition. To our knowledge, this is the first report of the prognosis of lead extraction in Japanese patients with CIED‐related infection, including lead‐related infective endocarditis.
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